Biogen (BIIB) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY26 EPS Guidance

Biogen (NASDAQ: BIIB) reported Q4 EPS of $1.99, $0.38 better than the analyst estimate of $1.61. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.21 billion.

GUIDANCE:

Biogen sees FY2026 EPS of $15.25-$16.25, versus the consensus of $14.92.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Active options: META SMCI MU SOFI GOOG NOK MSTR AVGO AMD HOOD
• Active options: TSLA NVDA AMZN GOOGL AAPL SPCX MSFT NFLX INTC